{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ceritinib&page=2",
    "query": {
      "intervention": "Ceritinib",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ceritinib&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T21:38:39.978Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02587650",
      "title": "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ALK Fusion Protein Expression",
        "BRAF wt Allele",
        "Invasive Skin Melanoma",
        "MET Fusion Gene Positive",
        "NRAS wt Allele",
        "NTRK1 Fusion Positive",
        "NTRK2 Fusion Positive",
        "NTRK3 Fusion Positive",
        "RET Fusion Positive",
        "ROS1 Fusion Positive",
        "Stage III Cutaneous Melanoma",
        "Stage IIIA Cutaneous Melanoma",
        "Stage IIIB Cutaneous Melanoma",
        "Stage IIIC Cutaneous Melanoma",
        "Stage IV Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "Capmatinib",
          "type": "DRUG"
        },
        {
          "name": "Ceritinib",
          "type": "DRUG"
        },
        {
          "name": "Entrectinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-03-26",
      "completion_date": "2018-07-12",
      "has_results": true,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02587650"
    },
    {
      "nct_id": "NCT02422589",
      "title": "A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ALK-positive Advanced Tumors"
      ],
      "interventions": [
        {
          "name": "ceritinib",
          "type": "DRUG"
        },
        {
          "name": "warfarin",
          "type": "DRUG"
        },
        {
          "name": "midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2015-10-23",
      "completion_date": "2017-12-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • San Antonio, Texas",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422589"
    },
    {
      "nct_id": "NCT03546894",
      "title": "A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anaplastic Lymphoma Kinase-positive",
        "Carcinoma Non-small-cell Lung"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        },
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Ceritinib",
          "type": "DRUG"
        },
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "Any FDA Approved ALK Inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2018-07-23",
      "completion_date": "2023-02-13",
      "has_results": false,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 1,
      "location_summary": "Maynard, Massachusetts",
      "locations": [
        {
          "city": "Maynard",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03546894"
    },
    {
      "nct_id": "NCT03611738",
      "title": "Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Lung Cancer",
        "Non-small Cell Lung Cancer Metastatic",
        "Non-small Cell Lung Cancer Stage IIIB",
        "Stage IV Non-small Cell Lung Cancer",
        "EGFR Negative Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ceritinib",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-02-01",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03611738"
    },
    {
      "nct_id": "NCT02605746",
      "title": "Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "ceritinib 750mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-02-17",
      "completion_date": "2019-07-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-11",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605746"
    },
    {
      "nct_id": "NCT02186821",
      "title": "Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumors With Aberrations in ALK or ROS1"
      ],
      "interventions": [
        {
          "name": "Ceritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2014-09-17",
      "completion_date": "2017-12-13",
      "has_results": true,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 21,
      "location_summary": "Santa Rosa, California • Denver, Colorado • Greenwood Village, Colorado + 17 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186821"
    },
    {
      "nct_id": "NCT01685060",
      "title": "LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "LDK378",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2012-11-26",
      "completion_date": "2016-03-29",
      "has_results": true,
      "last_update_posted_date": "2017-06-19",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 17,
      "location_summary": "Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01685060"
    },
    {
      "nct_id": "NCT02780128",
      "title": "Next Generation Personalized Neuroblastoma Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Next Generation Sequencing",
          "type": "GENETIC"
        },
        {
          "name": "Tumor Scans",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone marrow Tests",
          "type": "PROCEDURE"
        },
        {
          "name": "Physical Exam",
          "type": "OTHER"
        },
        {
          "name": "Eye Exam",
          "type": "OTHER"
        },
        {
          "name": "Labs",
          "type": "OTHER"
        },
        {
          "name": "Pregnancy Test",
          "type": "OTHER"
        },
        {
          "name": "Interviews",
          "type": "BEHAVIORAL"
        },
        {
          "name": "ECG",
          "type": "OTHER"
        },
        {
          "name": "Echocardiogram",
          "type": "OTHER"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Ceritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "GENETIC",
        "OTHER",
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Yael P Mosse",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 66,
      "start_date": "2016-07",
      "completion_date": "2022-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780128"
    },
    {
      "nct_id": "NCT01742286",
      "title": "Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ALK-activated Tumors"
      ],
      "interventions": [
        {
          "name": "Ceritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Months to 17 Years"
      },
      "enrollment_count": 83,
      "start_date": "2013-08-28",
      "completion_date": "2019-04-26",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01742286"
    },
    {
      "nct_id": "NCT02554591",
      "title": "Genomic Landscape of Ceritinib",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Non-small Lung Cancer",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2015-09-16",
      "completion_date": "2018-02-28",
      "has_results": false,
      "last_update_posted_date": "2018-03-05",
      "last_synced_at": "2026-09-24T21:38:39.978Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02554591"
    }
  ]
}